Login Register Cart 0
Generic placeholder image

Current Hypertension Reviews

Editor-in-Chief

ISSN (Print): 1573-4021
ISSN (Online): 1875-6506

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Meta-Analysis

ACEi/ ARB and Deaths of COVID-19 Patients

Author(s): Gulam Navi Azad and Anoop Kumar*

Volume 18, Issue 2, 2022

Published on: 23 August, 2022

Page: [158 - 162] Pages: 5

DOI: 10.2174/1573402118666220407093332

Price: $65

Abstract

The practice of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEi/ARB) in COVID-19 hypertensive patients is still an open question for clinicians to answer. The present study was conducted to find out the association between the use of ACEI/ARB and the mortality rate of COVID-19 patients. The search was conducted from December 2019 to October 2020 in PubMed to identify relevant published studies. RevMan 5 was used for the analysis of the data. The random-effect model was used to calculate the odds ratio. In total, 07 studies were found to be appropriate, reporting a total of 1,566 subjects. The odds ratio was found to be 0.86 [0.41, 1.81], indicating no association between ACEI/ARB and the mortality rate of COVID- 19 patients. In conclusion, we may suggest continuing the use of ACEi/ARB in COVID-19 patients till further pieces of evidence are generated.

Keywords: COVID-19, Angiotensin-converting enzyme inhibitor (ACEI), Angiotensin-receptor blocker (ARB), mortality, Rev Man 5, odd ratio.

« Previous
Graphical Abstract

[1]
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirusdisease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323(13): 1239-42.
[http://dx.doi.org/10.1001/jama.2020.2648] [PMID: 32091533]
[2]
Sanyaolu A, Okorie C, Marinkovic A, et al. Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med 2020; 2(8): 1-8.
[http://dx.doi.org/10.1007/s42399-020-00363-4] [PMID: 32838147]
[3]
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181(2): 271-280.e8.
[http://dx.doi.org/10.1016/j.cell.2020.02.052] [PMID: 32142651]
[4]
Albini A, Noonan DM, Pelosi G, Di Guardo G, Lombardo M. The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: Implications for ACE-inhibitor- and angiotensin II receptor blocker-based antihypertensive therapies-reply. Intern Emerg Med 2020; 15(8): 1583-4.
[http://dx.doi.org/10.1007/s11739-020-02436-7] [PMID: 32666177]
[5]
Zhang P, Zhu L, Cai J, et al. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res 2020; 126(12): 1671-81.
[http://dx.doi.org/10.1161/CIRCRESAHA.120.317134] [PMID: 32302265]
[6]
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 2009; 6(7): e1000097.
[http://dx.doi.org/10.1371/journal.pmed.1000097] [PMID: 19621072]
[7]
Conversano A, Melillo F, Napolano A, Fominskiy E, Spessot M, Ciceri F. RAAs inhibitors and outcome in patients with SARS-CoV-2 pneumonia. A case series study. Hypertension 2020; 76: e10-2.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.120.15312] [PMID: 32383626]
[8]
Felice C, Nardin C, Di Tanna GL, et al. Use of RAAS inhibitors and risk of clinical deterioration in COVID-19: Results from an Italian cohort of 133 hypertensives. Am J Hypertens 2020; 33(10): 944-8.
[PMID: 32511678]
[9]
Gao C, Cai Y, Zhang K, et al. Association of hypertension and antihypertensive treatment with COVID-19 mortality: A retrospective observational study. Eur Heart J 2020; 41(22): 2058-66.
[http://dx.doi.org/10.1093/eurheartj/ehaa433] [PMID: 32498076]
[10]
Meng J, Xiao G, Zhang J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect 2020; 9(1): 757-60.
[http://dx.doi.org/10.1080/22221751.2020.1746200] [PMID: 32228222]
[11]
Zhou X, Zhu J, Xu T. Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin-angiotensin system inhibitors. Clin Exp Hypertens 2020; 42(7): 656-60.
[http://dx.doi.org/10.1080/10641963.2020.1764018] [PMID: 32404011]
[12]
Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020; 5(7): 811-8.
[http://dx.doi.org/10.1001/jamacardio.2020.1017] [PMID: 32219356]
[13]
Li J, Wang X, Chen J, Zhang H, Deng A. Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) Infection in Wuhan China. JAMA Cardiol 2020; 5(7): 825-30.
[http://dx.doi.org/10.1001/jamacardio.2020.1624] [PMID: 32324209]
[14]
Lonn EM, Yusuf S, Jha P, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994; 90(4): 2056-69.
[http://dx.doi.org/10.1161/01.CIR.90.4.2056] [PMID: 7923694]
[15]
Schiffrin EL. Vascular and cardiac benefits of angiotensin receptor blockers. Am J Med 2002; 113(5): 409-18.
[http://dx.doi.org/10.1016/S0002-9343(02)01241-X] [PMID: 12401536]
[16]
Offringa A, Montijn R, Singh S, Paul M, Pinto YM, Pinto-Sietsma SJ. The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: Possible treatment options related to the renin-angiotensin system. Eur Heart J Cardiovasc Pharmacother 2020; 6(5): 317-25.
[http://dx.doi.org/10.1093/ehjcvp/pvaa053] [PMID: 32464637]
[17]
Zeng Z, Sha T, Zhang Y, Wu F, Hu H, Li H. Hypertension in patients hospitalized with COVID-19 in Wuhan, China: A single-center retrospective observational study. MedRxiv 2020.
[http://dx.doi.org/10.1101/2020.04.06.20054825]

Rights & Permissions Print Cite
Article Metrics
3
© 2024 Bentham Science Publishers | Privacy Policy